The Illinois Department of Public Health (IDPH) has guided development of an infection control tool called the XDRO registry. The purpose of the XDRO registry is two-fold:

1. **Improve inter-facility communication:** The registry provides efficient CRE information exchange across the spectrum of care.

2. **Improve CRE surveillance:** The registry stores CRE surveillance data and has features that can help facilities track their CRE submission history.

**Reporting Requirements**

- IDPH amended the Control of Communicable Diseases Code (77 Ill. Adm. Code 690) to require reporting of CRE to IDPH.
- As of November 1, 2013, the **first CRE-positive culture per patient stay** must be reported to the XDRO registry **within 7 calendar days** after the test result is finalized.
- All hospitals, hospital-affiliated clinical laboratories, independent or free-standing laboratories, longer-term care facilities, and long-term acute care hospitals in Illinois are required to report CRE isolates that meet surveillance criteria.

**CRE surveillance criteria**

Enterobacteriaceae (e.g., *E. coli*, *Klebsiella* spp, *Enterobacter* spp, *Proteus* spp, *Citrobacter* spp, *Serratia* spp, *Morganella* spp, or *Providentia* spp) with one of the following laboratory test results:

1. Molecular test (e.g., polymerase chain reaction [PCR]) specific for carbapenemase;
2. Phenotypic test (e.g., Modified Hodge) specific for carbapenemase production;
3. Susceptibility test (**for *E. coli* and *Klebsiella* spp only**): non-susceptible (intermediate or resistant) to ONE of the following carbapenems (doripenem, meropenem, or imipenem) AND resistant to ALL of the following third generation cephalosporins tested (ceftriaxone, cefotaxime, and ceftazidime). **Note: ignore ertapenem for this definition.**

**Highlighted Features**

- The XDRO Dashboard (shown at right) graphically shows data from a user’s facility and the state aggregate.
- The Search Registry function allows facilities to check whether a patient has been previously reported as CRE-positive.

For more information about and access to the XDRO registry, visit: [www.xdro.org](http://www.xdro.org)

For XDRO registry questions, contact: DPH.XRDORegistry@illinois.gov

*Revised 11/2014*
Report Carbapenem-Resistant Enterobacteriaceae (CRE) isolates to the XDRO registry

(1) Is the isolate in the Enterobacteriaceae family (e.g., Klebsiella, Escherichia coli, Enterobacter, Serratia, Proteus, others)?
   NO
   Do NOT Report: Pseudomonas, Acinetobacter, MRSA, or other non-Enterobacteriaceae isolates

   YES

(2) Did the isolate have a positive genotypic test (PCR) for a carbapenemase (e.g., KPC, NDM, VIM, IMP, OXA)?
   NO

   YES
   Report to the XDRO registry

   NO

(3) Did the isolate have a positive phenotypic test (e.g., Modified Hodge or MBL Etest) for carbapenemase production?
   NO

   YES
   Report to the XDRO registry

   NO

(4) Is the isolate E. coli or Klebsiella spp.?
   YES
   Do NOT Report

   NO

(5) Is the isolate non-susceptible (INTERMEDIATE or RESISTANT) to imipenem, meropenem, and/or doripenem?
   NO

   YES
   Do NOT Report: Isolates that are sensitive or intermediate to any third-generation cephalosporin

   NO

(6) Is the isolate RESISTANT to ALL third-generation cephalosporins tested (e.g., ceftriaxone, cefotaxime, ceftazidime, others)?
   NO

   YES
   Report to the XDRO registry

XDRO registry website: [www.xdro.org](http://www.xdro.org)  •  XDRO registry e-mail: DPH.XDROregistry@illinois.gov

Revised 7/2015